Liminatus Pharma, Inc. Warrants - LIMNW - Fundamentals

Feel free to try out our engine!Whenever you're ready, pick a plan!

Best Investments/trading ideas for the weekJoin our free webinar on September23,2026.

Insider Tracker is here!

‌
‌

‌

Let's get started...

‌

Breakdown	2022 12/31	2023 12/31	2025 12/31	TTM
REVENUE	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	📊
Cost of Revenue	0	0	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	📊
Gross Profit	0	0	0	--	📊
Gross Profit Growth (1Y)	--	--	--	--	📊
Gross Profit Growth (5Y)	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	📊
Operating Expenses	3	5	3	4	📊
Operating Expenses Growth (1Y)	--	+77.89%	-38.41%	+45.87%	📊
Operating Expenses Growth (5Y)	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	📊
Sell General Administrative	1	1	3	3	📊
Research and Development	2	4	0	1	📊
Other Income Expenses	0	0	0	--	📊
EBITDA	-3	-5	-10	-12	📊
EBITDA Growth (1Y)	--	-77.52%	-107.71%	-24.47%	📊
EBITDA Growth (5Y)	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	📊
Depreciation and Amortization	0	0	0	--	📊
Operating Income	-3	-5	-3	-4	📊
Operating Income Growth (1Y)	--	-77.89%	+38.41%	-36.98%	📊
Operating Income Growth (5Y)	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	📊
Interest Expense	0	0	0	--	📊
Pre Tax Income	-3	-5	-10	-13	📊
Tax Provision	0	0	0	--	📊
NET INCOME	-3	-5	-10	-13	📊
Net Income Growth (1Y)	--	-70.22%	-104.79%	-25.91%	📊
Net Income Growth (5Y)	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	📊
Basic EPS	0	0	-0.43	2.05	📊
Diluted EPS	0	0	-0.43	2.05	📊
Basic Average Shares	0	0	24	34	📊
Diluted Average Shares	0	0	24	34	📊

Breakdown	2022 12/31	2023 12/31	2025 12/31	TTM
REVENUE	0	0	0	--	📊
Revenue Growth (1Y)	--	--	--	--	📊
Revenue Growth (5Y)	--	--	--	--	📊
Revenue Growth (10Y)	--	--	--	--	📊
Cost of Revenue	0	0	0	--	📊
Cost of Revenue Growth (1Y)	--	--	--	--	📊
Cost of Revenue Growth (5Y)	--	--	--	--	📊
Cost of Revenue Growth (10Y)	--	--	--	--	📊
Gross Profit	0	0	0	--	📊
Gross Profit Growth (1Y)	--	--	--	--	📊
Gross Profit Growth (5Y)	--	--	--	--	📊
Gross Profit Growth (10Y)	--	--	--	--	📊
Operating Expenses	3	5	3	4	📊
Operating Expenses Growth (1Y)	--	+77.89%	-38.41%	+45.87%	📊
Operating Expenses Growth (5Y)	--	--	--	--	📊
Operating Expenses Growth (10Y)	--	--	--	--	📊
Sell General Administrative	1	1	3	3	📊
Research and Development	2	4	0	1	📊
Other Income Expenses	0	0	0	--	📊
EBITDA	-3	-5	-10	-12	📊
EBITDA Growth (1Y)	--	-77.52%	-107.71%	-24.47%	📊
EBITDA Growth (5Y)	--	--	--	--	📊
EBITDA Growth (10Y)	--	--	--	--	📊
Depreciation and Amortization	0	0	0	--	📊
Operating Income	-3	-5	-3	-4	📊
Operating Income Growth (1Y)	--	-77.89%	+38.41%	-36.98%	📊
Operating Income Growth (5Y)	--	--	--	--	📊
Operating Income Growth (10Y)	--	--	--	--	📊
Interest Expense	0	0	0	--	📊
Pre Tax Income	-3	-5	-10	-13	📊
Tax Provision	0	0	0	--	📊
NET INCOME	-3	-5	-10	-13	📊
Net Income Growth (1Y)	--	-70.22%	-104.79%	-25.91%	📊
Net Income Growth (5Y)	--	--	--	--	📊
Net Income Growth (10Y)	--	--	--	--	📊
Basic EPS	0	0	-0.43	2.05	📊
Diluted EPS	0	0	-0.43	2.05	📊
Basic Average Shares	0	0	24	34	📊
Diluted Average Shares	0	0	24	34	📊

Liminatus Pharma, Inc. Warrants - LIMNW - Fundamentals - Financial Statements